Relief Therapeutics Valuation
| RLFTF Stock | USD 4.33 0.13 2.91% |
At this time, the company appears to be overvalued. Relief Therapeutics holds a recent Real Value of $3.91 per share. The prevailing price of the company is $4.33. Our model determines the value of Relief Therapeutics from analyzing the company fundamentals such as Current Valuation of 102.36 M, shares owned by insiders of 3.68 %, and Return On Equity of -0.33 as well as examining its technical indicators and probability of bankruptcy. . In general, most investors support locking in undervalued entities and disposing overvalued entities since, at some point, asset prices and their ongoing real values will merge together.
Overvalued
Today
Please note that Relief Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Relief Therapeutics is based on 3 months time horizon. Increasing Relief Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Relief otc stock is determined by what a typical buyer is willing to pay for full or partial control of Relief Therapeutics Holding. Since Relief Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Relief OTC Stock. However, Relief Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.33 | Real 3.91 | Hype 4.33 | Naive 3.99 |
The real value of Relief OTC Stock, also known as its intrinsic value, is the underlying worth of Relief Therapeutics OTC Stock, which is reflected in its stock price. It is based on Relief Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Relief Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Relief Therapeutics Holding helps investors to forecast how Relief otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Relief Therapeutics more accurately as focusing exclusively on Relief Therapeutics' fundamentals will not take into account other important factors: Relief Therapeutics Total Value Analysis
Relief Therapeutics Holding is at this time anticipated to have takeover price of 102.36 M with market capitalization of 120.99 M, debt of 396 K, and cash on hands of 29.87 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Relief Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
102.36 M | 120.99 M | 396 K | 29.87 M |
Relief Therapeutics Investor Information
About 22.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.71. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Relief Therapeutics recorded a loss per share of 0.01. The entity had not issued any dividends in recent years. Based on the key indicators related to Relief Therapeutics' liquidity, profitability, solvency, and operating efficiency, Relief Therapeutics Holding is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Relief Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Relief Therapeutics has an asset utilization ratio of 1.32 percent. This implies that the OTC Stock is making $0.0132 for each dollar of assets. An increasing asset utilization means that Relief Therapeutics Holding is more efficient with each dollar of assets it utilizes for everyday operations.Relief Therapeutics Ownership Allocation
Relief Therapeutics owns a total of 4.39 Billion outstanding shares. Relief Therapeutics holds 3.68 pct. of its outstanding shares held by insiders and 22.16 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Relief Therapeutics Profitability Analysis
The company reported the revenue of 3.32 M. Net Loss for the year was (34.7 M) with profit before overhead, payroll, taxes, and interest of 2.57 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Relief Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Relief Therapeutics and how it compares across the competition.
About Relief Therapeutics Valuation
The otc valuation mechanism determines Relief Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Relief Therapeutics. We calculate exposure to Relief Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Relief Therapeutics's related companies.Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company was founded in 2013 and is based in Geneva, Switzerland. Mondobiotech Holding is traded on OTC Exchange in the United States.
8 Steps to conduct Relief Therapeutics' Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Relief Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Relief Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Relief Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Relief Therapeutics' revenue streams: Identify Relief Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Relief Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Relief Therapeutics' growth potential: Evaluate Relief Therapeutics' management, business model, and growth potential.
- Determine Relief Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Relief Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Relief Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Relief Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 4.1 B | |
| Forward Price Earnings | 1.3019 | |
| Retained Earnings | -69.8 M |
Complementary Tools for Relief OTC Stock analysis
When running Relief Therapeutics' price analysis, check to measure Relief Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relief Therapeutics is operating at the current time. Most of Relief Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relief Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relief Therapeutics' price. Additionally, you may evaluate how the addition of Relief Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |